Biohaven Ltd. 2023 Form 10-K Summary
Business context and reporting period
Biohaven is a clinical-stage biopharmaceutical company developing candidates in neuroscience, immunology and oncology. This annual report covers the fiscal year ended December 31, 2023; it does not provide a standalone fourth-quarter financial summary. The company reported no product revenue and has no approved products. Its financial statements include pre-October 2022 results from when the business was part of its former parent, so historical comparisons may not reflect standalone costs.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $373.3 million | $437.1 million |
| General and administrative expense | $62.8 million | $130.9 million |
| Total operating expenses / operating loss | $436.1 million | $567.9 million |
| Other income (expense), net | $26.5 million | $(1.9) million |
| Net loss | $408.2 million | $570.3 million |
| Net loss per share, basic and diluted | $5.73 | $12.75 |
| Cash used in operating activities | $331.7 million | $297.7 million |
At year-end, cash and cash equivalents were $248.4 million and marketable securities were $133.4 million, totaling $381.8 million; restricted cash was an additional $3.7 million. Current assets were $442.4 million and current liabilities $55.4 million. Total liabilities were $85.2 million, including $30.9 million of operating lease liabilities. The filing reports no borrowings or other debt balance. There was no gross margin to report because the company had no product sales.
The 2023 net loss narrowed by $162.1 million, while operating cash use increased by $34.0 million. Lower R&D and G&A expenses primarily reflected substantially lower non-cash share-based compensation and the absence of the 2022 Kv7 acquisition and milestone charges; these reductions were partly offset by higher spending on advancing programs. Other income benefited from investment income and transition-service revenue, and the 2022 comparison included a $10.0 million Artizan investment impairment.
Material changes, outlook and risks
- Biohaven completed an October 2023 public offering that generated approximately $242.4 million net proceeds. It also established an at-the-market offering program of up to $150 million; no shares had been sold under it by year-end. The company issued 721,136 shares valued at $21.8 million to Highlightll under a license amendment.
- Management stated that cash, cash equivalents and marketable securities were expected to fund planned expenses and commitments for at least 12 months from the filing date. It also expects to need additional capital before reaching profitability; no committed external funding source is disclosed.
- Troriluzole: The Phase 3 SCA trial missed its primary endpoint in the overall population. The FDA declined to file the SCA3 NDA for substantive review; the EMA validated the SCA application for review. Two Phase 3 OCD trials were ongoing, with an interim analysis for the first trial expected to produce topline results in Q2 2024.
- Other programs: Biohaven expected SMA Phase 3 taldefgrobep alfa topline data in the second half of 2024 and planned a Phase 2 obesity study. BHV-7000 epilepsy trials were expected to begin enrollment in Q1 2024, with additional mood-disorder trials planned. The company also outlined anticipated 2024 studies for several early-stage programs; these are forward-looking plans, not reported outcomes.
- Research commitments were $36.5 million, principally for CRO agreements, and operating lease payments totaled $39.8 million as of year-end. The filing also identifies potentially substantial contingent license milestones and royalties whose timing and likelihood are uncertain.
- Key risks include clinical failure or delay, regulatory uncertainty, dependence on third-party manufacturers and research providers, further financing needs and dilution, competition, reimbursement and pricing pressures, intellectual-property disputes, and cybersecurity threats. Biohaven said it had no material legal proceedings and no cybersecurity incident had materially affected it to date.
Important facts for investors to verify
- Progress and regulatory feedback on the SCA3 program following the FDA’s refusal to file, and the status and outcome of the EMA review.
- OCD interim-analysis results and the timing, design and outcome of the two Phase 3 trials.
- Actual cash burn, milestone and trial commitments, and whether the stated cash runway remains achievable without additional financing.
- Potential dilution from the $150 million ATM program, equity compensation and any future share-funded acquisitions or license payments.
- Execution and results of the planned SMA, epilepsy, obesity and other clinical programs; pipeline timelines may change.
- The filing reports an unqualified audit opinion and effective internal control over financial reporting as of December 31, 2023; monitor controls and compliance as the company operates as a large accelerated filer.